Bir Dawn Carter's Form 4 filing
Reata Pharmaceuticals Inc (RETA) · filed May 17, 2023
- Accession no.
- 0001209191-23-030167
- Filed
- May 17, 2023
- Trade date
- May 15-16, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 0 derivative transactions. Open-market sales total $109.8K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Bir Dawn CarterCIK 0001688712 | Officer (Chief Commercial Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 15, 2023 | Class A common stock | SSaleDisposed | −894 | $85.09 | −$76,070.46 | 31,302 | Direct | |
| May 16, 2023 | Class A common stock | SSaleDisposed | −417 | $80.96 | −$33,760.32 | 30,885 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.